{"product_id":"cagrisema","title":"CagriSema","description":"\u003cstyle\u003e\n.peptide-details {\n  border: 1px solid #8A97B5;\n  margin-bottom: 8px;\n  border-radius: 8px;\n  overflow: hidden;\n}\n.peptide-details summary {\n  cursor: pointer;\n  padding: 12px 16px;\n  font-weight: bold;\n  list-style: none;\n  display: flex;\n  align-items: center;\n  justify-content: space-between;\n}\n.peptide-details summary::-webkit-details-marker {\n  display: none;\n}\n.peptide-details summary::after {\n  content: '';\n  display: inline-block;\n  width: 8px;\n  height: 8px;\n  border-right: 1px solid #8A97B5;\n  border-bottom: 1px solid #8A97B5;\n  transform: rotate(45deg);\n  transition: transform 0.2s ease;\n  flex-shrink: 0;\n  margin-left: 10px;\n}\n.peptide-details[open] summary::after {\n  transform: rotate(-135deg);\n}\n.peptide-details .peptide-content {\n  padding: 16px;\n}\n\u003c\/style\u003e\n\n\u003ch3 class=\"fusion-title-heading title-heading-left fusion-responsive-typography-calculated\"\u003eProduct Description\u003c\/h3\u003e\n\n\u003cdetails class=\"peptide-details\" open\u003e\n\u003csummary\u003eOverview\u003c\/summary\u003e\n\u003cdiv class=\"peptide-content\"\u003e\n\u003cp\u003eCagrilintide–Semaglutide (CagriSema) is a fixed-dose combination of the long-acting amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide. It is being developed by Novo Nordisk as a once-weekly subcutaneous therapy for chronic weight management and type 2 diabetes. By combining two distinct but complementary mechanisms of action on glycaemic control and body weight, CagriSema represents a novel approach to metabolic disease research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e\n\n\u003cdetails class=\"peptide-details\"\u003e\n\u003csummary\u003eMechanism of Action\u003c\/summary\u003e\n\u003cdiv class=\"peptide-content\"\u003e\n\u003cp\u003eCagriSema exerts its effects through simultaneous activation of two complementary receptor pathways. Cagrilintide is a long-acting acylated amylin analogue that acts as a nonselective agonist for amylin receptors (AMYR) and calcitonin G protein-coupled receptors (CTR). This activation reduces food intake and promotes weight loss through central and peripheral mechanisms. Semaglutide is a long-acting, selective GLP-1 receptor agonist that promotes insulin secretion, inhibits gastric emptying and appetite, enhances autophagy, inhibits oxidative stress and apoptosis, and regulates mitochondrial function and lipid metabolism. Together, these agents provide complementary effects on energy intake, appetite control, and glycaemic regulation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e\n\n\u003cdetails class=\"peptide-details\"\u003e\n\u003csummary\u003eResearch Applications\u003c\/summary\u003e\n\u003cdiv class=\"peptide-content\"\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eObesity and Weight Management:\u003c\/strong\u003e Investigated for significant and sustained weight reduction in adults with overweight or obesity. In the REDEFINE 1 phase 3a trial, CagriSema (2.4 mg\/2.4 mg) demonstrated superior weight loss compared to semaglutide monotherapy and placebo. A once-weekly fixed-dose combination led to an average weight loss of −13.7%, compared to −3.4% with placebo, with 84% achieving ≥5% weight loss. A 32-week trial showed mean body weight change of −15.6% with CagriSema vs −5.1% with semaglutide.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eType 2 Diabetes Mellitus:\u003c\/strong\u003e Studied for glycaemic control in adults with type 2 diabetes. In the REIMAGINE 1 trial, CagriSema (2.4 mg each) achieved an estimated mean HbA1c reduction of −1.8 percentage points after 40 weeks. In the REIMAGINE 3 trial as an add-on to basal insulin, CagriSema (2.4 mg each) demonstrated a mean HbA1c reduction of −2.33%.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCardiometabolic Outcomes:\u003c\/strong\u003e Investigated for blood pressure reduction and broader cardiometabolic benefits in adults with overweight or obesity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAppetite and Energy Intake Studies:\u003c\/strong\u003e Employed to evaluate effects on ad libitum energy intake, craving control, hunger, satiety, and gastric emptying. Studies demonstrate CagriSema significantly reduces energy intake (63% reduction) and appetite without delaying gastric emptying.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e\n\n\u003cdetails class=\"peptide-details\"\u003e\n\u003csummary\u003eProduct Specifications\u003c\/summary\u003e\n\u003cdiv class=\"peptide-content\"\u003e\n\u003cp\u003e\u003cstrong\u003ePeptide Content:\u003c\/strong\u003e Cagrilintide and Semaglutide (fixed-dose combination per vial; concentrations vary by research protocol, e.g., 2.4 mg\/2.4 mg or 1.0 mg\/1.0 mg)\u003cbr\u003e\n\u003cstrong\u003eCAS Number:\u003c\/strong\u003e 1415456-99-3 (Cagrilintide); 910463-68-2 (Semaglutide)\u003cbr\u003e\n\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₁₉₄H₃₁₂N₅₄O₅₉S₂ (Cagrilintide); C₁₈₇H₂₉₁N₄₅O₅₉ (Semaglutide)\u003cbr\u003e\n\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 4,409.01 g\/mol (Cagrilintide); 4,113.58 g\/mol (Semaglutide)\u003cbr\u003e\n\u003cstrong\u003eSequence (Cagrilintide):\u003c\/strong\u003e {Eicosanedioic acid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH₂ (Disulfide bridge: Cys³-Cys⁸)\u003cbr\u003e\n\u003cstrong\u003eSequence (Semaglutide):\u003c\/strong\u003e His-[Aib]-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-[C18 diacid-γ-Glu-(AEEA)₂-Lys]-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly\u003cbr\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e ≥ 99%\u003cbr\u003e\n\u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilized powder\u003cbr\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Store at ≤ -20°C in a cool, dry place, protected from light and moisture\u003cbr\u003e\n\u003cstrong\u003eSolubility:\u003c\/strong\u003e Soluble in sterile water and DMSO; prepare working solutions per laboratory protocol\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/details\u003e\n","brand":"yuansensetech","offers":[{"title":"CS 5mg","offer_id":52038353584418,"sku":"CS5","price":175.0,"currency_code":"USD","in_stock":true},{"title":"CS 10mg","offer_id":52038353617186,"sku":"CS10","price":308.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1008\/2805\/3794\/files\/CS10.jpg?v=1783741691","url":"https:\/\/yuansensepeptide.com\/products\/cagrisema","provider":"Yuansensetech™","version":"1.0","type":"link"}